Cancer drug resistance study raises immune red flags

Once a cancer patient’s tumors develop resistance to chemotherapy, the prognosis can be poor. However, inhibiting a key gene involved in multidrug resistance, MDR1, has not improved outcomes. A new study offers a reason, revealing unintended downstream effects on immune system cells.